DOMS Industries (DOMS) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
9 Jul, 2026Executive summary
Achieved consolidated revenue growth of 24.4% year-over-year for FY25, driven by steady sales momentum, new product launches, Uniclan integration, and strategic acquisitions including SKIDO.
Board recommended a dividend of INR 3.15 per share, subject to approval.
Strengthened global presence through FILA partnership, enhancing export capabilities and product innovation.
Continued investment in manufacturing infrastructure, R&D, and capacity expansion to support operational efficiency and product differentiation.
Hygiene segment reported separately for the first time, reflecting impact of Uniclan and SKIDO acquisitions.
Financial highlights
Q4 FY25 consolidated revenue grew 26% year-over-year to INR 508.7 crores; FY25 revenue reached INR 1,912.6 crores, up from INR 1,537 crores in FY24.
Q4 FY25 EBITDA rose 16.2% to INR 88.3 crores; FY25 EBITDA grew 27.8% to INR 348.4 crores, margin expanded to 18.2%.
Q4 FY25 PAT up 9.3% to INR 51.3 crores; FY25 PAT up 33.7% to INR 213.5 crores; PAT margin for FY25 at 11.2%.
Gross profit margin for FY25 at 43.5%, up from 41.9% in FY24.
Operating cash flow for FY25 at INR 183.3 crores; significant investments in capex and acquisitions.
Outlook and guidance
FY26 revenue growth guidance of 18%-20% at consolidated level, including Uniclan.
EBITDA margin expected in the 16.5%-17.5% range; PAT margin around 10%.
CapEx planned at INR 225-250 crores annually for the next two years, focused on plant expansion and capacity additions.
Ongoing capacity expansion at Umbergaon, Gujarat, with first building to be operational by Q4FY26.
Unutilized IPO proceeds remain invested in fixed deposits and monitoring accounts, supporting future growth.
Latest events from DOMS Industries
- Revenue grew 17.6%, while inflation and flood losses pressured profits.DOMS
Q2 26/27 - Q4 recovery and export growth partly offset steep FY21 pandemic-driven losses.DOMS
Q4 20/21 - Revenue surged and profits recovered as operations normalized after COVID disruption.DOMS
Q4 21/22 - Strong FY24 growth and IPO funding underpin capacity expansion amid supply and cost risks.DOMS
Q4 23/24 - FY23 revenue and profit surged as capacity expansion and a 1:150 bonus issue advanced.DOMS
Q4 22/23 - Revenue up 19.2% YoY, but margins fell on cost pressures; expansion and Reynolds deal to drive growth.DOMS
Q1 26/27 - Q3 FY26 saw 18.2% revenue growth, 17.5% EBITDA margin, and robust expansion initiatives.DOMS
Q3 25/26 - Q2 FY26 saw strong revenue and profit growth, capacity expansion, and product diversification.DOMS
Q2 25/26 - Q3 FY25 revenue and profit surged, supported by acquisitions, capacity expansion, and IPO funds.DOMS
Q3 24/25